What if we learned that making a small change to your diet could improve key aspects of cognitive performance? The best part ...

Michael W. Schwartz UW Medicine Diabetes Institute, explains how the brain can be targeted to treat obesity and diabetes ...

AI tools are revolutionizing neuroscience, enabling researchers to predict study outcomes with 86% accuracy and uncover novel ...

When listeners detect excessive filler words, the brain's amygdala activates a subtle "threat" response, signaling uncertainty or or unreliability in the speaker.

While the concept of this gripping piece of science fiction is far-fetched, it touches on a question neuroscience has been ...

Jan. 22, 2025 — Thermal sensations are consciously differentiated as hot or cold by the brain; however, the neural mechanism that enables this differentiation is not well understood. To address ...

A study reveals that London taxi drivers prioritize complex and distant junctions during their initial "offline thinking" ...

Johnson & Johnson has struck a $14.6bn deal to buy neuroscience drugmaker Intra-Cellular Therapies, the US pharmaceutical ...

A former leader at DP World Dubai, Neetu transitioned seamlessly into entrepreneurship, where her leadership has set new ...

马萨诸塞州沃特敦 - 临床阶段生物技术公司Vigil Neuroscience, Inc. (NASDAQ: VIGL )宣布，其阿尔茨海默病 (AD)候选药物VG-3927将于2025年第三季度进入二期临床试验。这一决定是基于一期临床试验的积极结果，该试验证明了该药物的安全性、耐受性和药代动力学特性，表明其有潜力成为AD的每日一次口服疗法。

Investing.com -- Vigil Neuroscience , Inc. (NASDAQ: VIGL )的股价上涨14%，此前该公司报告了其VG-3927阿尔茨海默病 (AD)潜在治疗药物的第一阶段临床试验取得了积极结果。数据显示，VG-3927的安全性、耐受性以及药代动力学和药效学特征支持其作为AD每日一次口服治疗方案的进一步开发。